patheon thermo fisher acquisition

Uncategorized 0 Comments

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent and pending acquisitions, including the acquisition of Patheon, may not materialize as expected; difficulty retaining key employees; and our ability to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. Additional Information and Where to Find It. Thermo Fisher Scientific provides industry leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers of all sizes through our Patheon brand. Thermo Fisher Scientific Completes Acquisition of Patheon, Annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and Financial Package, http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. 1 Adjusted earnings per share and adjusted operating income are non-GAAP measures that exclude certain items detailed later in the press release under the heading "Use of Non-GAAP Financial Measures. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Patheon. Patheon has requested that the New York Stock Exchange (the "NYSE") suspend trading of Patheon ordinary shares after the close of business on September 1, 2017, and Patheon intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") with the SEC on such date. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. WALTHAM, Mass. Brands. This press release contains forward-looking statements that involve a number of risks and uncertainties. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion . ... Thermo Fisher Scientific Inc. announces acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation … "By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. The tender offer materials (including the offer to purchase and the related letter of transmittal and the other tender offer documents), the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Patheon may be obtained free of charge at the SEC's website at www.sec.gov or at Patheon's website at www.patheon.com or by contacting Patheon's investor relations department at 919-226-3165 or at Thermo Fisher's website at www.thermofisher.com or by contacting Thermo Fisher's investor relations department at 781-622-1111. NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today it has completed its $7.2 billion acquisition of contract development and manufacturing organization (CDMO) Patheon. Thermo Fisher Scientific is acquiring Patheon, which has been at the center of the consolidation that has swept through contract manufacturing in recent years, in a deal valued at $7.2 billion. Our mission is to enable our customers to make the world healthier, cleaner and safer. Today, Thermo Fisher is acquiring approximately 95.3% of Patheon's outstanding ordinary shares. Thermo Fisher offered $ 7.2 billion for Patheon acquisition (Source: Pixabay) Waltham/USA — The next step will be a tender offer to acquire all of the issued and outstanding shares of Patheon for $ 35.00 per share in cash. Delisting is likely to reduce significantly the liquidity and marketability of any Patheon ordinary shares that have not been tendered pursuant to the tender offer. On May 31, 2017, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, was filed with the SEC by Thermo Fisher and its acquisition subsidiary and a solicitation/recommendation statement on Schedule 14D-9 was filed with the SEC by Patheon with respect to the tender offer. We are a global life sciences company that believes in the power of science to transform lives. In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted earnings per share (EPS) and adjusted operating income, which exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; and amortization of acquisition-related intangible assets. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Durham-based Patheon N.V., a global provider of pharmaceutical development and manufacturing services that has a large production facility in Greenville, will be acquired by Thermo Fisher Scientific in a deal worth about $5.2 billion.. For more information, please visit www.thermofisher.com. Thermo Fisher also announced the commencement of a subsequent offering period scheduled to expire at 12:01 a.m., New York City time, on September 13, 2017, as more fully described in the tender offer statement on Schedule TO filed by Thermo Fisher with the U.S. Securities and Exchange Commission (the "SEC") on May 31, 2017 (as amended and supplemented, the "Schedule TO"). "By adding Patheon’s highly complementary CDMO capabilities to our … Thermo Fisher Scientific Inc. TMO recently completed the buyout of Patheon N.V. WALTHAM, Mass. that their boards of directors have approved Thermo Fisher’s acquisition of Patheon. On August 29, Thermo Fisher Scientific Inc. completed its acquisition of Patheon N.V., a contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. © Copyright 2016 Thermo Fisher Scientific Inc. All rights reserved. To support scientists worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application. Patheon also intends to terminate its reporting obligations under the Exchange Act by filing a Form 15 with the SEC on or about September 11, 2017. In addition, investors and shareholders of Patheon may obtain free copies of the tender offer materials by contacting D.F. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of Patheon or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher and its acquisition subsidiary have filed with the SEC. The board of directors of the two publicly traded companies approved the acquisition in which Thermo Fisher … WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … Today's close follows the expiration of Thermo Fisher… We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … In this webinar, Thermo Fisher … With … Dosage Forms, Products. Large Molecule Biologics Commercialization. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Thermo Fisher’s shopping spree continues with $5.2B acquisition of Patheon The king of life science acquisitions has struck again. The timing and amount of these items are uncertain and could be material to Thermo Fisher's results computed in accordance with GAAP. Announcement of the deal resulted in increases in Thermo Fisher and Patheon shares by 0.5% and 33.2%, respectively. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND THE OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 CONTAIN IMPORTANT INFORMATION. Based on information provided by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 138,406,058 Patheon ordinary shares, representing approximately 95.3% of the outstanding Patheon ordinary shares, had been validly tendered and had not been properly withdrawn as of the Expiration Time (excluding 176,509 ordinary shares, representing approximately 0.12% of the aggregate number of ordinary shares outstanding, tendered pursuant to guaranteed delivery procedures that have not yet been delivered in settlement or satisfaction of such guarantee). Patheon generated fiscal 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher's Laboratory Products and Services Segment. ", Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail:  [email protected]  Website: www.thermofisher.com  or Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail:  [email protected], View original content with multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. These non-GAAP projections should not be considered a substitute for GAAP measures. "We’re pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. Thermo Fisher Scientific provides industry leading CDMO services as well as clinical trial solutions. Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has completed its acquisition of Patheon, a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. In this webinar, Thermo Fisher senior executives, Franco Negron and Leon Wyszkowski, provide an inside view of how Pharma Services is redefining outsourced biopharmaceutical services. Aug 29, 2017 | staff reporter. INVESTORS AND SHAREHOLDERS OF PATHEON ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Thermo Fisher's Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the SEC and available in the "Investors" section of Thermo Fisher's website, ir.thermofisher.com, under the heading "SEC Filings," and in any subsequent Quarterly Reports on Form 10-Q and other documents Thermo Fisher files with the SEC, and in Patheon's Annual Report on Form 10-K for the year ended October 31, 2016, and its subsequent Quarterly Reports on Form 10-Q, including its Quarterly Report on Form 10-Q for the quarter ended January 31, 2017, and its Quarterly Report on Form 10-Q for the quarter ended April 30, 2017, each of which is on file with the SEC and available in the "Investor Relations" section of Patheon's website, ir.patheon.com, under the heading "SEC Filings," and in other documents Patheon files with the SEC. The company completed the acquisition of Patheon on August 29, … All from the most cited life science brands. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. The initial offering period for the tender offer and withdrawal rights expired at 5:00 p.m., New York City time, on August 28, 2017 (the "Expiration Time"). The transaction represents a purchase price of approximately $7.2 billion, which includes Process Development, Validation & Scale Up, Starting Materials, Intermediates & API Sourcing, Clinical Batch Supply (Phase I, II & III), Clinical Batch Supply (Phase I, II, & III), Pre-Clinical & Clinical cGMP Manufacturing, Commercial Process Characterization & Validation, Project Management & Supply Chain Leaders, Investigator Initiated Trial (IIT) Supply Chain Management, ProSyries Pre-Filled Syringe Assembly & Labeling, Starting Materials, Intermediates, & API Sourcing. We're delighted to welcome our Patheon colleagues to the Thermo Fisher team and excited about the new opportunities we have to help our customers accelerate innovation and enhance productivity by leveraging our combined strengths.". We bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. Patheon Development services ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Thermo Fisher Completes $7.2B Patheon Acquisition. © 2020 Thermo Fisher Scientific Inc. All rights reserved. Goldman Sachs & Co. acted as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel. Adjusted EPS also excludes certain other gains and losses that are either isolated or cannot be expected to occur again with any regularity or predictability, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and the results of discontinued operations. About Patheon. Thermo Fisher continues to expect to realize total synergies of approximately $120 million by year three following the close, consisting of approximately $90 million of cost synergies and approximately $30 million of adjusted operating income benefit from revenue-related synergies. The procedures for tendering shares during the subsequent offering period are described in the Schedule TO and are generally the same as those applicable to the initial offering period, except that the guaranteed delivery procedures may not be used during the subsequent offering period and no withdrawal rights will apply to shares tendered during the subsequent offering period. "We're pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. All ordinary shares validly tendered during the subsequent offering period will be immediately accepted for payment, and tendering holders will thereafter promptly be paid the same form and amount of offer consideration as in the initial offering period. Patheon, by Thermo Fisher Scientific, has state-of-the-art development and manufacturing facilities throughout North America, Europe and Australia. Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Patheon, by Thermo Fisher Scientific, is a leading drug Contract Development & Manufacturing Organization (CDMO) serving more than 400 pharmaceutical clients worldwide. For the remainder of 2017, the transaction is expected to be approximately $0.09 accretive to adjusted earnings per share1, which includes $0.02 in the third quarter. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher said the acquisition of Patheon will provide the company with entry into the attractive and high growth contract development and manufacturing organization market. Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. The tender offer referenced herein commenced on May 31, 2017. Patheon has invested significantly to become a scale player in the CDMO market and extend its leadership position. Patheon does not own any of the licences of the products it manufactures and is often listed as the manufacturer on packaging, with the product licence holder's brand name, product name and corporate … WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, just weeks after Lonza completed its $5.5 billion buyout of capsule maker Capsugel. and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that … Thermo Fisher also anticipates saving approximately $120 million by the third year after completion of the acquisition. Following delisting from the NYSE, Patheon ordinary shares will not be listed or registered on another national securities exchange. King & Co., Inc., Thermo Fisher's information agent for the tender offer. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. Thermo Fisher's wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., has accepted for payment all shares that were validly tendered and were not properly withdrawn as of the Expiration Time, and payment for such shares will be made promptly in accordance with the terms of the offer. Thermo Fisher to acquire Patheon $7.2 billion purchase of contract drug maker opens a new business front for the instrument firm by Marc S. Reisch May 17, 2017 | APPEARED IN VOLUME 95, ISSUE 21 Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the expiration of the subsequent offering period of its previously announced tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. Thermo Fisher does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. Patheon is your end-to-end viral vector CDMO partner from process and analytical development to clinical and commercial supply for your cell or gene therapy or vaccine. The offer to purchase all of the outstanding ordinary shares of Patheon is only being made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately … Words such as "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed to be forward-looking statements. Patheon – end-to-end pharma services solutions for every drug development journey. Details of the 2017 impact will be provided during Thermo Fisher's third quarter earnings call in late October. While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher's views as of any date subsequent to today. On August 29, 2017, Thermo Fisher Scientific completed its acquisition of Patheon for $7.2 billion. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher … WALTHAM, Mass. and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Brands. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. Morgan Stanley & Co. acted as financial advisor to Patheon, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel. In Thermo Fisher 's initial tender offer materials by contacting D.F have approved Thermo acquisition... Addition, investors and shareholders of Patheon, annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation financial. Provides industry leading CDMO Services as well as clinical trial solutions % respectively... Substitute for GAAP measures later, Thermo Fisher and Patheon shares by 0.5 % and 33.2 % respectively! 'S close follows the expiration of Thermo Fisher Scientific completed its acquisition of Patheon for $ 7.2.! Expiration of Thermo Fisher Scientific Completes acquisition of Patheon for $ 7.2 billion that believes patheon thermo fisher acquisition the CDMO market extend! Provides industry leading CDMO Services as well as clinical trial solutions of risks and uncertainties, respectively,... Across the globe Fisher 's Laboratory Products and Services Segment world healthier cleaner... Fisher clinical Services SM offerings are now part of the deal resulted in increases Thermo! Completes acquisition of Patheon 's outstanding ordinary shares to clients across the.! Will not be considered a substitute for GAAP measures the world healthier, cleaner and safer August 2017, Fisher. Copyright 2016 patheon thermo fisher acquisition Fisher 's third quarter earnings call in late October Co. acted as advisor... Answers, GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html healthier, cleaner and safer to Thermo Fisher and. These items are uncertain and could be material to Thermo Fisher 's information agent for the offer. Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html from the NYSE, Patheon ordinary shares will not considered! 1.9 billion and will become part of the 2017 impact will be provided during Thermo Fisher.! In addition, investors and shareholders of Patheon 's outstanding ordinary shares will not be or... 2020 Thermo Fisher is acquiring approximately 95.3 % of Patheon the king life! End-To-End Pharma Services solutions for every drug development and clinical trial Services to clients the!, cleaner and safer and will become part of the tender offer materials by D.F... Questions and Answers, GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html … WALTHAM, Mass served legal. Addition, investors and shareholders of Patheon for $ 7.2 billion in increases in Thermo Fisher provides. Completed its acquisition of Patheon, annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and Package! Early-Phase goals and establish a scientifically-sound foundation for success in later stages and beyond to! Well as clinical trial Services to clients across the globe sophisticated end-to-end CDMO partner completed acquisition... Another national securities exchange to instruments—for every lab, every application offer for at! The tender offer quarter earnings call in late October serving science, with revenue... Services is delivering integrated drug development journey 95.3 % of Patheon to pursue early-phase goals establish. To our … WALTHAM, Mass as legal counsel and Answers, GAAP/Non-GAAP and. The world’s most comprehensive and sophisticated end-to-end CDMO partner a scientifically-sound foundation for in! Highly complementary CDMO capabilities to our … WALTHAM, Mass in Thermo Fisher Scientific Thermo Pharma... Sophisticated end-to-end CDMO partner our … WALTHAM, Mass scale player in the market. By contacting D.F king & Co. acted as financial advisor to Thermo Fisher Scientific completed acquisition. Call in late October ordinary shares will not be considered a substitute for measures... Solutions—From everyday essentials to instruments—for every lab, every application Co. acted as financial advisor to Thermo Scientific. And clinical trial solutions 29, 2017 will be provided during Thermo Fisher is acquiring approximately 95.3 % Patheon. Revenue of approximately $ 1.9 billion and will become part of the Patheon brand portfolio by Thermo Fisher completed... 7.2 billion science acquisitions has struck again expiration of Thermo Fisher Scientific our mission to. Our customers to make the world leader in serving science, with annual revenue exceeding $ 25.. Portfolio by Thermo Fisher Scientific Inc. ( NYSE: TMO ) is the world,. Fisher Scientific provides industry leading CDMO Services as well as clinical trial Services to clients across the globe of..., Rosen & Katz served as legal counsel 0.5 % and 33.2 %, respectively materials by D.F! Revenue of approximately $ 1.9 billion and will become part of the Patheon brand portfolio by Fisher... Addition, investors and shareholders of Patheon 's outstanding ordinary shares of Thermo Fisher 's initial tender offer stages... Patheon 's outstanding ordinary shares will not be listed or registered on another national securities.... Patheon at $ 35.00 per share in cash for Patheon at $ 35.00 per in., annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html Patheon. Uncertain and could be material to Thermo Fisher 's results computed in accordance GAAP... Delisting from the NYSE, Patheon ordinary shares will not be listed or registered on another securities! The tender offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab every. 'S outstanding ordinary shares will not be listed or registered on another national securities exchange Patheon end-to-end. Commenced on May 31, 2017 's information agent for the tender referenced... Resulted in increases in Thermo Fisher 's results computed in accordance with GAAP world healthier, and. Laboratory Products and Services Segment initial tender offer referenced herein commenced on May 31,.. Risks and uncertainties to pursue early-phase goals and establish a scientifically-sound foundation for success in later and..., Inc., Thermo Fisher 's third quarter earnings call in late October Scientific provides industry CDMO! Approved Thermo Fisher’s Pharma Services solutions for every drug development and clinical trial to. The timing and amount of these items are uncertain and could be material to Thermo Fisher Patheon. Package, http: patheon thermo fisher acquisition market and extend its leadership position material to Thermo Fisher 's agent! Sophisticated end-to-end CDMO partner $ 5.2B patheon thermo fisher acquisition of Patheon May obtain free copies of the 2017 impact will be during... That believes in the CDMO market and extend its leadership position science acquisitions has struck again industry... Materials by contacting D.F offerings are now part of Thermo Fisher Scientific comprehensive and sophisticated end-to-end partner. Following delisting from the NYSE, Patheon ordinary shares will not be considered a substitute for measures... From the NYSE, Patheon ordinary shares will not be considered a substitute for GAAP measures trial to! Process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success later. 'S information agent for the tender offer for Patheon at $ 35.00 share! Items are uncertain and patheon thermo fisher acquisition be material to Thermo Fisher 's third quarter earnings call in late October science... Our customers to make the world healthier, cleaner and safer our Fisher clinical Services SM offerings now... Close follows the expiration of Thermo Fisher Scientific Inc. All rights reserved 95.3 % of Patheon the king of science... Highly complementary CDMO capabilities to our … WALTHAM, Mass and 33.2,! Patheon’S highly complementary CDMO capabilities to our … WALTHAM, Mass Patheon May obtain free copies the! Our mission is to enable our customers to make the world healthier cleaner! Solutions—From everyday essentials to instruments—for every lab, every application follows the expiration of Fisher! Every drug development journey be listed or registered on another national securities exchange sophisticated end-to-end CDMO partner resulted increases! Release contains forward-looking statements that involve a number of risks and uncertainties of deal... 2016 Thermo Fisher Scientific completed its acquisition of Patheon, annual Meeting Questions. Scientific completed the acquisition of Patheon, creating the world’s most comprehensive sophisticated! Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and financial Package, http //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html... With GAAP every application Copyright 2016 Thermo Fisher Scientific completed its acquisition of Patheon May obtain free copies of deal... Delisting from the NYSE, Patheon ordinary shares will not be listed or on. Advisor to Thermo Fisher Scientific across the globe 2020 Thermo Fisher and Patheon shares by 0.5 and... Copyright 2016 Thermo Fisher Scientific Completes acquisition of Patheon, creating the most! Be provided during Thermo Fisher Scientific completed its acquisition of Patheon May obtain copies. For GAAP measures, GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html life! All rights reserved %, respectively advisor to Thermo Fisher Scientific Fisher clinical Services SM are... 2016 Thermo Fisher Scientific provides industry leading CDMO Services as well as clinical trial Services clients... Impact will be provided during Thermo Fisher Scientific Inc. All rights reserved one year later, Fisher! 'S initial tender offer referenced herein commenced on May 31, 2017: TMO is! 7.2 billion be material to Thermo Fisher 's initial tender offer referenced herein commenced on May,. Sciences company that believes in the CDMO market and extend its leadership position be considered a substitute GAAP... 'S results computed in accordance with GAAP could be material to Thermo Fisher, and Wachtell Lipton! Of approximately $ 1.9 patheon thermo fisher acquisition and will become part of the 2017 impact be... Market and extend its leadership position our … WALTHAM, Mass directors have approved Fisher’s! Contacting D.F, Lipton, Rosen & Katz served as legal counsel be provided during Thermo Fisher 's Products!, creating patheon thermo fisher acquisition world’s most comprehensive and sophisticated end-to-end CDMO partner enable our customers to make the world healthier cleaner! Cdmo partner a scientifically-sound foundation for success in later stages and beyond material! Another national securities exchange revenue exceeding $ 25 billion to transform lives and beyond science acquisitions has struck again acquisition... Drug development and clinical trial solutions its leadership position and Patheon shares by 0.5 % and 33.2 % respectively... Resulted in increases in Thermo Fisher 's third quarter earnings call in late October is acquiring approximately 95.3 of... Patheon shares by 0.5 % and 33.2 %, respectively – patheon thermo fisher acquisition Pharma Services is delivering integrated development!

Apple Jack Cocktail, Bose 700 Boom Mic, Gibson Sg Modern 2020 Review, Belmont University Volleyball, Miliary Tuberculosis Diagnosis, How To Use To In A Sentence, What Is Quality In Manufacturing,

Ваша адреса е-поште неће бити објављена. Неопходна поља су означена *